Brightseed and Haleon Announce Strategic Collaboration to Harness AI for Small Molecule Discovery and Human Health Innovation
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Haleon (LSE: HLN), a global leader in consumer health, and Brightseed, the pioneer in AI-driven discovery of bioactive compounds, announced a new collaboration to advance the discovery of plant-based, small molecules with the potential to improve human health. This partnership will leverage Brightseed's proprietary AI platform, Forager®, as a solution to accelerate scientific insights into the natural world and support Haleon's mission to deliver innovative, science-led health solutions.
"By integrating Forager® into its research ecosystem, Haleon is furthering its commitment to improving everyday health with scientifically validated, nature-inspired solutions.'
Share
Forager is a cutting-edge, artificial intelligence platform that maps bioactives—compounds in plants and other natural sources that influence human biology—and identifies their mechanisms of action. In addition to this collaboration agreement, Brightseed will work with Haleon to make Forager directly accessible to Haleon's scientists, enabling efficient natural bioactive discovery by integrating AI-powered discovery into their research and product development pipelines.
'We are thrilled with this partnership that augments our scientific capabilities towards groundbreaking advancements,' said Sandrine Alvarado, VP and Head of Future Horizons R&D at Haleon. 'This collaboration is pivotal in accelerating discoveries and innovations that are firmly rooted in superior, trusted science and the highest standards of scientific integrity.'
Brightseed's AI-driven approach to bioactive discovery has already yielded key insights into plant compounds with potential applications across metabolic health, gut health, immunity, and more. This collaboration aligns with Haleon's commitment to science-backed innovation and the pursuit of next-generation natural health solutions.
'Forager's AI not only accelerates innovation, it also expands possibilities in ways that would have been otherwise intractable, ' said Lee Chae, Co-Founder and CEO at Brightseed. ' With this collaboration, Haleon is poised to translate those possibilities into an engine for growth. By integrating Forager® into its research ecosystem, Haleon is furthering its commitment to improving everyday health with scientifically validated, nature-inspired solutions.'
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
About Brightseed
Brightseed is an AI-driven biosciences company unlocking the power of nature to improve human health. Its proprietary AI platform, Forager®, identifies bioactive compounds in plants and natural sources and maps their impact on human biology at an unprecedented scale. Brightseed partners with global companies in consumer health, functional ingredients, and nutrition to accelerate the discovery and commercialization of science-backed health solutions.
For more information, visit Haleon.com and Brightseedbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Lead Plaintiff Deadline is June 16, 2025 for Investors of Ibotta, Inc.
NEW YORK, NY - June 8, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ibotta, Inc. ('Ibotta' or the 'Company') (NYSE: IBTA) on behalf of Ibotta investors. CLICK HERE TO JOIN THE CASE If you are an investor in Ibotta and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than June 16, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to consumers through the Ibotta Performance Network. On April 18, 2024, Ibotta conducted its Initial Public Offering ('IPO'), offering 6,560,700 million shares of Class A common stock at a price of $88 per share. The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that; (i) Ibotta's data measurement system did not provide accurate, precise, and real time client campaign and consumer data measurement; (ii) the Company's business mix had shifted and was generating less revenue; and (iii) Ibotta had 'exhausted' its clients' budgets, negatively impacting fourth quarter 2024 revenue and expected first quarter 2025 revenue. According to the action, on February 26, 2025, after market hours, in connection with reporting fourth quarter 2024 and full year 2024 financial results, Ibotta's CEO Bryan W. Leach ('CEO Leach') explained just how deficient Ibotta's data measurement technology was by stating that 'it has become clear that we need to bring to market a more rigorous form of measurement that goes beyond the industry standard return on ad spend, or ROAS, framework.' Further CEO Leach allegedly announced that Ibotta would transform into a programmatic advertising company, which according to the complaint demonstrates that, at the time of the IPO, Ibotta's data measurement infrastructure was not suited for heavy reliance on third party platforms. On this news, the price of Ibotta's stock fell $29.08, or nearly 46%, to close at $34.09 on February 27, 2025, more than 60% lower than the IPO price of $88 per share. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. View the original release on
Yahoo
4 hours ago
- Yahoo
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space
Hims & Hers is gaining market share in the telehealth sector and has a long runway to disrupt the healthcare industry. It is acquiring a company in order to enter Europe. The stock is expensive, but it may still be a great investment over the long term. 10 stocks we like better than Hims & Hers Health › Telehealth has gone through a major boom-and-bust cycle. One promising stock emerging from the bust is Hims & Hers (NYSE: HIMS). Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, the company is taking a lot of share in the telehealth market. The stock has traded up 449% since going public, and it is up a staggering 158% in the past year. Disruptive innovation helped bring shareholders of Hims & Hers stock major gains. But does that make the stock a buy today? People in the United States get frustrated dealing with health insurance -- as you may know from personal experience. Hims & Hers aims to slowly disrupt the market with an innovative approach that bypasses insurers. It helps customers easily get generic medications that help deal with sexual health, hair loss, mental health, and other common concerns, by having prescriptions and shipments sent straight to their doors through monthly subscriptions. This model has helped Hims & Hers dominate the telehealth prescription market and reach $1.78 billion in trailing-12-month revenue. It's now trying to further expand its offerings by adding the branded weight loss drug Wegovy to its marketplace through a partnership with Novo Nordisk (NYSE: NVO). Previously, Hims & Hers sold weight loss drugs under an exemption because of supply shortages for the products, but with those shortages now resolved, it has to work with patent holders such as Novo Nordisk. Along with weight loss, it's also aiming to get into testosterone and menopause-related prescriptions. Today, Hims & Hers has 2.4 million active customers. Management believes there are over 100 million people who could utilize one of its products, giving the company a huge runway to grow. A key factor will be the new partnership for marketing Wegovy, which is an expensive subscription at an introductory discount offer of $549 a month. Usage of such drugs is growing like a weed, and could be a new growth avenue for Hims & Hers to pursue. Another huge step for Hims & Hers is international expansion. While countries vary in their approaches to healthcare and insurance, most people want easy-to-use products, affordable prices, and convenient at-home shipping regardless of where they live. Management hopes to supercharge international growth with its proposed buyout of competitor Zava in Europe. Zava serves the western European market with 1.3 million active customers in the United Kingdom, France, Germany, and Ireland. The combined company can utilize Hims & Hers' marketing expertise, increasing scale, and partnerships to bring this sought-after model to Europe. Global disruption of the healthcare space will give Hims & Hers an even larger runway for growth, while also allowing it to invest in new innovations -- including at-home patient testing and its own compounding manufacturing facility. Hims & Hers has grand ambitions to disrupt healthcare with its direct-to-consumer model, and Zava will give it even more scale to keep accelerating growth. It will be exciting to see what the combined company can do over the next decade. You can feel the excitement with Hims & Hers and its explosive revenue growth. Sales grew 111% year over year last quarter, and are expected to hit at least $2.3 billion in 2025. (They were just $100 million in 2020.) The company has a goal of reaching $6.5 billion in sales by 2030, which would make it one of the fastest-growing companies in the world this decade. This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, which is a high trailing earnings multiple even for a fast-growing company. However, revenue is growing so quickly and with such high margins that the company may grow into this high valuation by the end of the decade. As noted, management has a goal of $6.5 billion in revenue in 2030. With 20% bottom-line profit margins -- easily doable with 77% gross profit margin over the last 12 months -- that would equate to roughly $1.3 billion in annual earnings in 2030. Today, the market cap is $12.3 billion, which would mean a P/E of just around 9.5 by 2030 if the market cap did not change (which is an unlikely scenario, but demonstrates that there is potential for the valuation to drop). Even with some shareholder dilution that raises the number of shares outstanding, the stock would be trading at a P/E of around 10 to 12 at the current share price (which is also likely to change). If you believe this rapid growth will continue over the long term, Hims & Hers stock will grow into its valuation. If you have any doubts about this pace of growth, shares should be considered overvalued at the moment. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space was originally published by The Motley Fool
Yahoo
5 hours ago
- Yahoo
In 1 year, the Phoenix share price could turn £1,000 into…
The Phoenix Group (LSE:PHNX) share price has had a pretty terrific first half in 2025, climbing by over 25%. And yet, despite this upward trajectory, continued dividend hikes by management means investors can still secure an impressive 8.4% yield. Of course, a high yield's worthless if the dividend can't be sustained. Yet, looking at the group's latest results, that doesn't seem to be a major issue for Phoenix. Operating cash generation in 2024 grew 22% to £1.4bn. That was firmly ahead of expectations, with management not initially expecting to reach this level until 2026. Needless to say, hitting financial targets two years early is an encouraging sign. To top things off, the group's Solvency II Shareholder Capital Coverage ratio also stands tall at 172%. In other words, the balance sheet has ample financial resources to act as a buffer should macroeconomic conditions take a turn for the worse. With that in mind, it's not hard to see why income investors are excited about what the future holds. So how much money can investors make with a £1,000 investment today? Investing in high-quality businesses for the long term is a proven strategy for building wealth in the stock market. However, valuation can have a significant impact on performance. And right now, despite the strong financial results, it seems most of this growth's already baked into Phoenix Group's share price. The most optimistic price forecast currently projects this stock could rise to 718p if its new private market-focused investment products prove popular among customers. That's roughly 11% higher than where the shares currently trade, suggesting that a £1,000 investment today could be worth £1,110 by this time next year, along with an extra £84 from dividends. However, as previously stated, this is the most optimistic forecast. By comparison, Berenberg Bank, Morgan Stanley, and Bank of America all have price targets between 640p and 650p, suggesting the stock's already fairly valued. If these more conservative projections prove correct, the returns on a £1,000 investment could be almost entirely driven by dividends. An 8.4% gain from shareholder payouts is nothing to scoff at. After all, that's roughly double what most high-interest savings accounts currently offer. And with dividends expected to grow further next year, this yield could climb even higher if the Phoenix share price does decide to remain stagnant. However, it's important to highlight some key risks surrounding this business. Like many insurance businesses, Phoenix is highly sensitive to changes in interest rates. While the business currently boasts a large capital buffer, volatility induced by shifting interest rates could harm asset values, applying pressure on the group's solvency ratios and, in turn, dividends. Another significant threat to watch carefully is the group's ongoing pivot to becoming a more capital-light enterprise. I've already highlighted the potential gains from management expanding its private market offer. However, success in this strategy is far from guaranteed. And if customers are reluctant to explore these new opportunities, growth could fall short of expectations. All things considered, Phoenix could be a compelling income investment to consider. However, it comes with considerable risks that management doesn't necessarily have a high level of control over. And with other lower-risk income opportunities to explore, I'm not rushing to buy right now. The post In 1 year, the Phoenix share price could turn £1,000 into… appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Bank of America is an advertising partner of Motley Fool Money. Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
